Natural compounds against nonalcoholic fatty liver disease: A review on the involvement of the LKB1/AMPK signaling pathway
N Omidkhoda, S Mahdiani, AW Hayes… - Phytotherapy …, 2023 - Wiley Online Library
Although various therapeutic approaches are used to manage nonalcoholic fatty liver
disease (NAFLD), the best approach to NAFLD management is unclear. NAFLD is a liver …
disease (NAFLD), the best approach to NAFLD management is unclear. NAFLD is a liver …
Effect of changes in metabolic enzymes and transporters on drug metabolism in the context of liver disease: Impact on pharmacokinetics and drug–drug interactions
S Armani, A Geier, T Forst, U Merle… - British Journal of …, 2024 - Wiley Online Library
Changes in the pharmacokinetic and resulting pharmacodynamic properties of drugs are
common in many chronic liver diseases, leading to adverse effects, drug interactions and …
common in many chronic liver diseases, leading to adverse effects, drug interactions and …
Digoxin pharmacokinetics in patients with obesity before and after a gastric bypass or a strict diet compared with normal weight individuals
Abstract Background and Objective Several drugs on the market are substrates for P-
glycoprotein (P-gp), an efflux transporter highly expressed in barrier tissues such as the …
glycoprotein (P-gp), an efflux transporter highly expressed in barrier tissues such as the …
Unravelling the complexities of non-alcoholic steatohepatitis: The role of metabolism, transporters, and herb-drug interactions
Nonalcoholic fatty liver disease (NAFLD) is a mainstream halting liver disease with high
prevalence in North America, Europe, and other world regions. It is an advanced form of …
prevalence in North America, Europe, and other world regions. It is an advanced form of …
What is the impact of metabolic dysfunction–associated steatotic liver disease on drug transport and metabolism?
CG Dietrich, A Geier - Expert Opinion on Drug Metabolism & …, 2024 - Taylor & Francis
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the leading chronic liver
disease all over the world. MASLD is already considered the second most common …
disease all over the world. MASLD is already considered the second most common …
Exploring the interconnected between type 2 diabetes mellitus and nonalcoholic fatty liver disease: Genetic correlation and Mendelian randomization analysis
W Ni, Y Lu, W Wang - Medicine, 2024 - journals.lww.com
Epidemiological and clinical studies have indicated a higher risk of nonalcoholic fatty liver
disease (NAFLD) and type 2 diabetes mellitus (T2DM), implying a potentially shared genetic …
disease (NAFLD) and type 2 diabetes mellitus (T2DM), implying a potentially shared genetic …
AMELIORATIVE EFFECT OF PIOGLITAZONE AND ROUSVASTATIN ON HFD/STZ-INDUCED HEPATIC INJURY IN RATS
AM SADEK, MH ABDEL-RAHEEM… - Assiut Veterinary …, 2024 - journals.ekb.eg
Approximately 90% of people with diabetes mellitus (DM) are estimated to have type 2
diabetes (T2DM), which causes hepatic dysfunction. Pioglitazone is an antidiabetic …
diabetes (T2DM), which causes hepatic dysfunction. Pioglitazone is an antidiabetic …